Pfizer (PFE), known for its successful drugs and vaccines, is at a technical turning point with its stock currently priced at $25.04. The question is whether the ascending trendline, in place since April, will continue to support the stock’s price. This trendline has endured numerous tests over the last eight months, acting as a solid base for the stock’s uptrend.<\/p>\n
If the stock maintains this support, the upward trend persists. Breaking this line could lead to a stock decline to around $21.97, a 12% drop from current levels. The $21.97 target is calculated from the structure’s geometry and past momentum, representing a potential ending point if the trendline fails.<\/p>\n
Traders face a clear decision: bulls must maintain the trendline, while bears should wait for a confirmed break. Volume levels during any potential breakdown are crucial, as heavy selling suggests a genuine change in sentiment. Despite market complexities, PFE presents a clear technical scenario with the trendline as the dividing line between continued growth and a potential retracement to the low $22s.<\/p>\n
As of today, December 18th, 2025, we are watching Pfizer trade around $25.04, where its entire uptrend for the past eight months is at stake. A single ascending trendline has supported the stock since late April, and our immediate actions depend entirely on whether it holds. This line is the battlefield between buyers and sellers right now.<\/p>\n
For those of us leaning bullish, the strategy is to see this support line hold and use it as a low-risk entry point. We might consider buying January 2026 call options with a strike price around $26 or selling cash-secured puts below the trendline, such as at the $24 strike. This approach bets on a bounce from this critical technical floor.<\/p>\n
Supporting this view, we’ve seen encouraging news flow recently, with Pfizer reporting positive Phase 2 trial data for its next-generation antiviral drug just last month. Furthermore, their Q3 2025 earnings in October showed a 4% revenue beat, driven by stronger-than-expected sales in its oncology division. These fundamentals could provide the catalyst for buyers to defend the trendline.<\/p>\n
If we anticipate a breakdown, however, patience is key until we see a daily close below that trendline. A decisive break would signal a move toward the $21.97 target, making the purchase of February 2026 put options an attractive strategy. Selling a bear call spread above the current price could also be a way to profit from a decline or sideways action.<\/p>\n
This bearish outlook is bolstered by concerns over the upcoming 2026 patent cliff for one of its key cardiovascular drugs, which analysts estimate could impact revenues by over $3 billion annually. Adding to this, competitor Eli Lilly recently received expanded approval for its weight-loss treatment, intensifying the competition in a market Pfizer is still trying to penetrate. We saw a similar pattern in late 2023 when patent concerns drove the stock to multi-year lows before it found its footing.<\/p>\n
Looking back, we remember the stock’s significant decline after the pandemic-era highs of the early 2020s, making this current eight-month uptrend the most sustained recovery we’ve seen since then. A failure here would feel like a return to the post-pandemic weakness and could erase much of the goodwill built up this year. The stakes are therefore higher than just a simple technical breakdown.<\/p>\n
Finally, implied volatility will be a key indicator for our derivative trades in the coming days. As PFE sits on this knife’s edge, a sharp move either way will likely cause volatility to expand, making options more expensive. We should monitor volume on any move; a breakdown on high volume would give us the strongest confirmation to commit to a bearish position.<\/p>\n","protected":false},"excerpt":{"rendered":"
Pfizer\u2019s stock hovers at a critical trendline, threatening a 12% drop if key support fails soon.<\/p>\n","protected":false},"author":62,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[59],"tags":[],"class_list":["post-37249","post","type-post","status-publish","format-standard","hentry","category-live-updates"],"acf":{"acf_article_selection_author":null},"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/posts\/37249","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/users\/62"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/comments?post=37249"}],"version-history":[{"count":0,"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/posts\/37249\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/media?parent=37249"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/categories?post=37249"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.vtmarkets.com\/en-ca\/wp-json\/wp\/v2\/tags?post=37249"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}